In Vivo Anticoagulant and Antiplatelet Effect of D-Phe-Pro-Arg-H and D-MePhe-Pro-Arg-H

Summary

D-Phe-Pro-Arg-H and D-MePhe-Pro-Arg-H synthetized in our institute were administered to mice, rats, rabbits and beagle dogs. The kinetics of the anticoagulant and antiplatelet effect was recorded by measuring various clotting parameters, platelet count and aggregation, and evaluated as proposed by Verstraete and Verwilghen. The minimum effective doses were found to be 0.25-0.5 mg kg^-1h^-1 by intravenous continuous infusions and 0.5-1.0 mg/kg by single injections. The dose-dependent prolongation of clotting times appeared after application within minutes and returned to baseline values as a function of dose. Blood level of the inhibitors was determined by a bioassay. Unlike heparin, no higher starting dose was required to reach the anticoagulant threshold level, i.e. 0.03-0.1 ¼g/ml whole blood. The peptides did not cause significant changes in platelet count and function or in hemodynamic parameters (blood pressure, heart rate and ECG) and in respiration. They blocked platelet aggregation induced by thrombin ex vivo specifically. No rebound effect or bleeding could be demonstrated even after subtoxic doses of the compounds. The onset of the anticoagulant and antithrombotic effect appeared within 60 min after single oral doses and lasted for 3-6 h. In close correlation with the anticoagulant effect a complete or significant inhibition of platelet aggregation induced by thrombin ex vivo could also be recorded by using 5-10 mg/kg doses.

• References

• 1 Thomson JM. (ed) Blood Coagulation and Haemostasis. A Practical Guide. 2nd ed. Churchill Livingstone; Edinburgh: 1980
• 2 Hijikata A, Okamoto S, Mori E, Kinjo K, Kikumoto R, Tonomura S, Tamao Y, Hara H. In vitro and in vivo studies of a new series of synthetic thrombin inhibitors (OM-inhibitors). Thromb Res (Sup-pi II) 1976; 8: 83-89
• 3 Wallis RB. Inhibition of thrombin, a key step in thrombosis. Drugs of Today 1989; 25: 597-605
• 4 Packham MA. Platelet function inhibitors. Thromb Haemostas 1983; 60: 610-619
• 5 Bagdy D, Barabäs E, Szell E, Bajusz S. In vitro inhibition of blood coagulation by tripeptide aldehydes. A retrospective screening study focused on the stable D-MePhe-Pro-Arg-HH₂S0₄ . Thromb Haemostas 1992; 67: 325-330
• 6 Bajusz S, Barabäs E, Szell E, Bagdy D. Peptide aldehyde inhibitors of the fibrinogen-thrombin reaction. In: Peptides: Chemistry, Structure and Biology. Walter R, Meienhofer J. (eds) Ann Arbor Sei Publ Inc; Ann Arbor, MI: 1975. pp 603-608
• 7 US Patent 4,399,065 (1983) to Bajusz S, Széll E, Barabäs E, Bagdy D.
• 8 US Patent 4,703,036 (1987) to Bajusz S, Széll E, Bagdy D, Barabäs E, Diöszegi M, Fittier Zs, Jözsa F, Horväth G, Tomori E.
• 9 Bajusz S, Szell E, Bagdy D, Barabäs E, Horväth Gy, Diöszegi M, Fittier Zs, Szabö G, Juhäsz A, Tomori E, Szilägyi G. Highly active and selective anticoagulants: D-Phe-Pro-Arg-H, a free tripeptide aldehyde prone to spontaneous inactivation, and its stable N-methyl derivative, D-MePhe-Pro-Arg-H. J Med Chem 1990; 33: 1729-1735
• 10 Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 184: 927-929
• 11 Verstraete M, Verwilghen R. Hematological disorders. In: Drug Treatment. Principles and Practice of Clinical Pharmacology and Therapeutics. Avery G. (ed) 2nd ed. Churchill-Livingstone; Edinburgh: 1990. p919
• 12 Markwardt F, Klöcking HP, Nowak G. Antithrombin und Antiplasminwirkung von 4-Amidinophenylbrenztraubensäure (APPA) in vivo. Thromb Diathes Haemorrh 1970; 24: 240-247
• 13 Markwardt F. Gerinnungsphysiologische Analyse der Wirkung synthetischer Thrombin-Inhibitoren. Thromb Diathes Haemorrh 1972; 27: 99-106
• 14 Markwardt F. Pharmacological control of blood coagulation by synthetic, low molecular weight inhibitors of clotting enzymes. A new concept of anticoagulants. Trends Pharm Sei 1980; 1: 152-157
• 15 Hauptmann J, Kaiser B, Markwardt F, Nowak G. Anticoagulant and antithrombotic action of novel specific inhibitors of thrombin. Thromb Haemostas 1980; 43: 118-123
• 16 Hauptmann J, Kaiser B, Markwardt F. Anticoagulant action of synthetic tight binding inhibitors of thrombin. Thromb Res 1985; 39: 771-775
• 17 Hara H, Tamao Y, Kikumoto R, Okamoto S. Effect of a synthetic thrombin inhibitor, MCI-9038, on experimental models of disseminated intravascular coagulation in rabbits. Thromb Haemostas 1987; 57: 165-170
• 18 Cadroy Y, Caranobe C, Bernat A, Maffrand JP, Sie P, Boneu B. Antithrombotic and bleeding effects of a new synthetic direct thrombin inhibitor and of standard heparin in the rabbit. Thromb Haemostas 1987; 58: 764-767
• 19 Kaiser B, Markwardt F. Experimental studies on the antithrombotic action of a highly effective synthetic thrombin inhibitor. Thromb Haemostas 1986; 55: 194-196
• 20 Stuerzebecher J. Inhibitors of thrombin. In: The Thrombin Vol 1. Machovich R. (ed) CRC Press; Boca Raton, CA: 1986. pp 131-160
• 21 Hauptmann J, Markwardt F. Pharmakologie synthetischer ThrombinInhibitoren. Beitrag zur WirkstofforschungH. 26 Oehme P, Löwe H, Göres E. (eds). Inst. f. Wirkstofforschung; Berlin: 1986
• 22 Kettner Ch, Shaw E. D-Phe-Pro-Arg • CH₂C1 - A selective affinity label for thrombin. Thromb Res 1979; 14: 969-973
• 23 Bagdy D, Barabâs É, Diöszegi M, Bajusz S, Fehér A. Comparative studies on the anticoagulant effect of D-Phe-Pro-Arg-H (1) and D-Phe-Pro-Arg• CH₂C1 (2). Thromb Haemostas 1983; 50: 53
• 24 Collen D, Matsuo D, Stassen JM, Kettner Ch, Shaw E. In vivo studies of a synthetic inhibitor of thrombin. J Lab Clin Med 1982; 39: 771-775
• 25 Goodman LS, Gilman A. In: The Pharmacological Basis of Therapeutics. 2nd ed. Macmillan Pubi Co Inc; New York: 1968. p. 1520
• 26 Hermán F, Hadházy P, Magyar K, Bagdy D, Barabás É, Kovács G. Effects of GYKI-14766 on blood coagulation and platelet function of beagle dogs. Abstract 20th FEBS Meeting Budapest: 1990. P-Th 037 256